tradingkey.logo

Nexalin Technology Inc

NXL
查看詳細走勢圖
0.515USD
-0.105-16.95%
收盤 02/06, 16:00美東報價延遲15分鐘
9.37M總市值
虧損本益比TTM

Nexalin Technology Inc

0.515
-0.105-16.95%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-16.95%

5天

-9.67%

1月

-27.68%

6月

-42.79%

今年開始到現在

-7.72%

1年

-86.16%

查看詳細走勢圖

TradingKey Nexalin Technology Inc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Nexalin Technology Inc當前公司基本面數據相對非常健康,最新ESG揭露屬於行業領先水平。增長潛力穩定。當前估值合理,在醫療設備與耗材行業排名116/205位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為4.00。中期看,股價處於下降通道。近一個月,市場表現非常差,但技術面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Nexalin Technology Inc評分

相關信息

行業排名
116 / 205
全市場排名
300 / 4521
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Nexalin Technology Inc亮點

亮點風險
Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
業績增長期
公司處於發展階段,最新年度總收入168.72K美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入168.72K美元
估值高估
公司最新PE估值-0.80,處於3年歷史高位
機構減倉
最新機構持股722.74K股,環比減少52.01%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉177.92K股
活躍度增加
近期活躍度增加,過去20天平均換手率1.05

分析師目標

基於 1 分析師
買入
評級
4.000
目標均價
+676.85%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Nexalin Technology Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Nexalin Technology Inc簡介

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
公司代碼NXL
公司Nexalin Technology Inc
CEOWhite (Mark)
網址https://nexalin.com
KeyAI